Efficacy and safety of meloxicam in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue 2, 1997, Pages 282-290

  Lemmel, Ernst Martin ^a   Bolten, Wolfgang ^b   Burgos Vargas, Ruben ^c   Platt, Philip ^d   Nissilä, Martti ^e   Sahlberg, Dick ^a   Björneboe, Olav ^f   Baumgartner, Hubert ^g   Valat, Jean Paul ^h   Franchimont, Paul ^a   Bluhmki, Erich ⁱ   Hanft, Gertraud ⁱ   Distel, Manuel ^j  

^a Staatliches Rheumakrankenhaus ^*

^b Rheumaklinik Wiesbaden   (Germany)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^f MARTINA HANSENS HOSPITAL   (Norway)

^g SCHULTHESS CLINIC   (Switzerland)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

cyclooxygenase 2 inhibitor; meloxicam; nonsteroidal antiinflammatory drug; rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; GOLD; HYDROXYCHLOROQUINE; MELOXICAM; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS ULCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PAIN; SAFETY; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0031042556     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Engelhardt G. Homma D, Schnitzler C: Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995;44:548-55.
2. Engelhardt G, Bögel R, Schnitzler C, Ultzmann R: Meloxicam: Influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 1996;51:21-8.
3. Türck D, Roth W, Busch U: A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996;(suppl 1)35:13-6.
4. Lauffen H, Leitpolt M: The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharm Ther Toxicol 1986;24:48-52.
5. Gonzales JP, Todd PA: Tenoxicam: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1987;34:289-310.
6. Arnett FC, Edworthy SM, Block DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
8. Pincus T, Summary JA, Soraci SA, Walston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford health questionnaire. Arthritis Rheum 1983;26:1346-53.
9. Pincus TH, Callahan LF, Brooks RH, et al: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic and laboratory measures. Ann Intern Med 1989;110:259-66.
10. Jones E, Hanly JG, Mooney R, et al: Strength and function in the normal and rheumatoid hand. J Rheumatol 1991;18:1313-8.
11. Solgaard S, Kristiansen B, Jensen JS: Evaluation of instruments for measuring grip strength. Acta Orthop Scand 1984;55:569-71.
12. Guidelines for the Clinical Evaluation of Anti-Inflammatory and Antirheumatic Drugs (Adults and Children). US Department of Health and Human Services, Public Health Service, Food and Drug Administration, Washington DC; 1988.
13. Karch FE, Lasagna L: Adverse drug reactions. J Am Med Assoc 1975;234:1236-41.
14. Schneider F: Die AA-Amyloidose bei entzuendlich-rheumatischen Erkrankungen. Ein klinischer Erfahrungsbericht. Z Rheumatol 1992;51:177-82.
15. Reginster JY, Distel M, Bluhmki E: A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 1996;(suppl 1)35:17-21.
16. Huskisson EC, Ghozlan R, Kurthen R, Degner FL, Bluhmki E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996;(suppl 1)35:29-34.
17. Ritchie DM, Boyle JA, McInness JM, et al: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
18. Wojtulewski JA, Schattenkirchner M, Barceló P, et al: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;(suppl 1)35:22-8.
19. Huskisson EC, Narjes H, Bluhmki E, Degner F: Comparison of meloxicam 15 mg and piroxicam 30 mg in a 3-week, double-blind trial in RA (abstr). Presented at 8th APLAR Congress, Melbourne, Australia; 1996.
20. Distel M, Mueller C, Bluhmki E, Fries J: Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 1996;(suppl 1)35:68-77.
21. Lund B, Distel M, Bluhmki E: Comparison of 3 doses of meloxicam for OA of knee: Double-blind placebo controlled study (abstr). Presented at 8th APLAR Congress, Melbourne, Australia; 1996.
22. Hosie J, Distel M, Bluhmki E: A long term study of meloxicam 15 mg once daily in osteoarthritis (OA) of the hip or knee (abstr). Rheumatol Eur 1995;(suppl 3)24:325, E52.
23. Williams HJ, Ward JR, Dahl SL, et al: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702-13.
24. Jacob GB, Hart KK, Mullane JB, Lutins S, Lee TY: Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr Ther Res 1983;33:703-13.
25. Weisman MH: Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis. Clin Ther 1986;8:427-38.
26. Dixon JS, Bird HA, Sitton NG, Pickup ME, Wright V: C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1984;13:39-44.
27. Littmann BH, Drury CE, Zimmerer RO, Stack CB, Law CG: Rheumatoid arthritis treated with tenidap and piroxicam. Arthritis Rheum 1995;38:29-37.
28. 2-receptor antagonists. Med Toxicol 1988;3:430-48.
29. Mayall B, Poggi G, Parkin JD: Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480-4.
30. Al-Awadhi A, Dale P, McKendry RJR: Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993;20:1121-5.
31. Sanada M, Takai K: Aplastic anaemia associated with piroxicam. Br J Haematol 1991;77:256-7.
32. Garcia S, Belda J, Linares M, et al: Prioxicam-induced agranulocytosis. Drug Intel Clin Pharm 1988;22:1003.
33. Miescher PA, Pola W: Haematological effects on non-narcotic analgesics. Drugs 1986;(suppl 4)32:90-108.
34. Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol 1991;31:588-98.
35. Porile JL, Bakris GL, Garella S: Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: A review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol 1990;30:468-75.
36. Khalil H, Molinary E, Stoller JK: Diclofenac (Voltaren)-induced eosinophilic pneumonitis. Case report and review of the literature. Arch Intern Med 1993;153:1649-52.
37. Hargreaves MR, Mowat AG, Benson MK: Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: Report of five cases and review of published reports. Thorax 1992;47:628-33.
38. McKendry RJR, Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6.
39. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
40. Whittle BJR, Vane JR: A biochemical bias for the gastrointestinal toxicity of non-steroid antirheumatoid drugs. Arch Toxicol 1984;7:315-22.
41. Roth SH, Bennett RE: Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987;147:2093-100.
42. Larkai EN, Smith JL, Lidsky MD, et al: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
43. Vane JR, Botting RM: New insights into the mode of anti-inflammatory drugs. Inflamm Res 1995;44: 1-10.
44. Vane JR: Towards a better aspirin. Nature 1994;367:215-6.
45. Battistini B, Botting R, Bakhle YS: COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 1994;7:501-12.
46. Churchill L, Graham AG, Shih C-L, Pauletti D, Farina PR, Grob PM: Selective inhibition of human cyclooxygenase 2 by meloxicam. Inflammopharmacology 1996;4:125-35.
47. Pairet M, Engelhardt G: Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting R, eds. Improved Non-steroid Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors. Dordrecht/Boston/London: Kluwer Academic Publishers, 1996.
48. Vane J, Botting RM: New insights into the mode of action of anti-inflammatory drugs. Agents Actions 1994;44:1-10.
49. Vane JR: NSAIDs, COX-2 inhibitors and the gut (letter). Lancet 1995;346:1105-6.